Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein

Reynaria Pitts; Elise Gunzburger; Christie M. Ballantyne; Philip J. Barter; David Kallend; Lawrence A. Leiter; Eran Leitersdorf; John J.V. McMurray; Stephen J. Nicholls; Eric J. Niesor; Anders G. Olsson; Prediman K. Shah; Jean Claude Tardif; John Kittelson; Gregory G. Schwartz

doi:10.1016/j.jacc.2016.09.932

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein

Reynaria Pitts, Elise Gunzburger, Christie M. Ballantyne, Philip J. Barter, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J.V. McMurray, Stephen J. Nicholls, Eric J. Niesor, Anders G. Olsson, Prediman K. Shah, Jean Claude Tardif, John Kittelson, Gregory G. Schwartz

Heart And Vascular Health

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	2488-2490
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	68
Issue number	22
DOIs	https://doi.org/10.1016/j.jacc.2016.09.932
Publication status	Published or Issued - 6 Dec 2016

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2016.09.932

Cite this

Pitts, R., Gunzburger, E., Ballantyne, C. M., Barter, P. J., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., Niesor, E. J., Olsson, A. G., Shah, P. K., Tardif, J. C., Kittelson, J., & Schwartz, G. G. (2016). Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. Journal of the American College of Cardiology, 68(22), 2488-2490. https://doi.org/10.1016/j.jacc.2016.09.932

@article{7803db402c264704bbdf4589716647e9,

title = "Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein",

author = "Reynaria Pitts and Elise Gunzburger and Ballantyne, {Christie M.} and Barter, {Philip J.} and David Kallend and Leiter, {Lawrence A.} and Eran Leitersdorf and McMurray, {John J.V.} and Nicholls, {Stephen J.} and Niesor, {Eric J.} and Olsson, {Anders G.} and Shah, {Prediman K.} and Tardif, {Jean Claude} and John Kittelson and Schwartz, {Gregory G.}",

note = "Funding Information: Please note: The dal-OUTCOMES (A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome) trial was funded by F. Hoffmann-La Roche. Dr. Ballantyne has received research support from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, the National Institutes of Health, the American Heart Association, and the American Diabetes Association (ADA); and is also a consultant for Roche. Dr. Barter has received research support from Merck, Pfizer, and the National Health and Medical Research Council of Australia; has ownership interest in Nil; has served on the advisory board of Merck, Pfizer, Amgen, Sanofi-Regeneron, Novartis, Kowa, Roche, and Eli Lilly; and has received honoraria from Amgen, AstraZeneca, CSL-Behring, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi-Regeneron. Dr. Kallend was an employee of F. Hoffmann-LaRoche at the time the dal-OUTCOMES trial was performed; and is currently an employee of The Medicines Company, Zurich, Switzerland. Dr. Leiter has received research funding from Aegerion, Amgen, The Medicines Company, Merck, Pfizer, Regeneron, and Sanofi; has served on the advisory board of Aegerion, Amgen, Merck, and Sanofi-Regeneron; and has provided continuing medical education on behalf of Amgen, Merck, and Sanofi-Regeneron. Dr. Leitersdorf is a consultant for Novartis, AstraZeneca, Sanofi, and Amgen; serves on advisory boards for Novartis and Cerenis; and has received research grants from Amgen, Merck, and Pfizer. Dr. Niesor was a former employee of F. Hoffman-La Roche; and is currently consulting for AstraZeneca, Cerenis, and Nestl{\'e}. Dr. McMurray, through his institution, has received funding from AbbVie, Amgen, Cardiorentis, GlaxoSmithKline, Novartis, Pfizer, Roche, and Sanofi. Dr. Nicholls has received research support from Amgen, Anthera, Eli Lilly, Cerenis, AstraZeneca, Novartis, Resverlogix, and Sanofi-Regeneron; he is also a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Kowa, Novartis, Merck, Takeda, Roche, Pfizer, and Sanofi-Regeneron. Dr. Olsson has received research grants from Amgen, AstraZeneca, Karobio, Merck, Pfizer, Roche, and Sanofi; and has consulted for AstraZeneca, Merck Sharp and Dohme, Merck, Pfizer, and Roche. Dr. Tardif has received research support from Amarin, AstraZeneca, DalCor, Eli Lilly, Hoffmann-LaRoche, Merck, Pfizer, Sanofi, Cymabay, Novartis, and Servier; has received honoraria from Hoffmann-LaRoche, Pfizer, Servier, AstraZeneca, DalCor, and Valeant; is a shareholder of DalCor; and is an author of a patent that has the findings of genotype-dependent results of dalcetrapib on clinical outcomes as its basis. Dr. Kittelson has received consulting fees from Bayer Healthcare, Cystic Fibrosis Foundation Therapeutics, Novo Nordisk, Genentech, and BioMarin; and has received honoraria for steering committee participation from CPC Clinical Research. Dr. Schwartz, through his institution, has received research grants from Cerenis, The Medicines Company, Resverlogix, Roche, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Dr. Pitts and Ms. Gunzburger contributed equally to this work. ",

year = "2016",

month = dec,

day = "6",

doi = "10.1016/j.jacc.2016.09.932",

language = "English",

volume = "68",

pages = "2488--2490",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "22",

}

Pitts, R, Gunzburger, E, Ballantyne, CM, Barter, PJ, Kallend, D, Leiter, LA, Leitersdorf, E, McMurray, JJV, Nicholls, SJ, Niesor, EJ, Olsson, AG, Shah, PK, Tardif, JC, Kittelson, J & Schwartz, GG 2016, 'Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein', Journal of the American College of Cardiology, vol. 68, no. 22, pp. 2488-2490. https://doi.org/10.1016/j.jacc.2016.09.932

TY - JOUR

T1 - Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein

AU - Pitts, Reynaria

AU - Gunzburger, Elise

AU - Ballantyne, Christie M.

AU - Barter, Philip J.

AU - Kallend, David

AU - Leiter, Lawrence A.

AU - Leitersdorf, Eran

AU - McMurray, John J.V.

AU - Nicholls, Stephen J.

AU - Niesor, Eric J.

AU - Olsson, Anders G.

AU - Shah, Prediman K.

AU - Tardif, Jean Claude

AU - Kittelson, John

AU - Schwartz, Gregory G.

N1 - Funding Information: Please note: The dal-OUTCOMES (A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome) trial was funded by F. Hoffmann-La Roche. Dr. Ballantyne has received research support from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, the National Institutes of Health, the American Heart Association, and the American Diabetes Association (ADA); and is also a consultant for Roche. Dr. Barter has received research support from Merck, Pfizer, and the National Health and Medical Research Council of Australia; has ownership interest in Nil; has served on the advisory board of Merck, Pfizer, Amgen, Sanofi-Regeneron, Novartis, Kowa, Roche, and Eli Lilly; and has received honoraria from Amgen, AstraZeneca, CSL-Behring, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi-Regeneron. Dr. Kallend was an employee of F. Hoffmann-LaRoche at the time the dal-OUTCOMES trial was performed; and is currently an employee of The Medicines Company, Zurich, Switzerland. Dr. Leiter has received research funding from Aegerion, Amgen, The Medicines Company, Merck, Pfizer, Regeneron, and Sanofi; has served on the advisory board of Aegerion, Amgen, Merck, and Sanofi-Regeneron; and has provided continuing medical education on behalf of Amgen, Merck, and Sanofi-Regeneron. Dr. Leitersdorf is a consultant for Novartis, AstraZeneca, Sanofi, and Amgen; serves on advisory boards for Novartis and Cerenis; and has received research grants from Amgen, Merck, and Pfizer. Dr. Niesor was a former employee of F. Hoffman-La Roche; and is currently consulting for AstraZeneca, Cerenis, and Nestlé. Dr. McMurray, through his institution, has received funding from AbbVie, Amgen, Cardiorentis, GlaxoSmithKline, Novartis, Pfizer, Roche, and Sanofi. Dr. Nicholls has received research support from Amgen, Anthera, Eli Lilly, Cerenis, AstraZeneca, Novartis, Resverlogix, and Sanofi-Regeneron; he is also a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Kowa, Novartis, Merck, Takeda, Roche, Pfizer, and Sanofi-Regeneron. Dr. Olsson has received research grants from Amgen, AstraZeneca, Karobio, Merck, Pfizer, Roche, and Sanofi; and has consulted for AstraZeneca, Merck Sharp and Dohme, Merck, Pfizer, and Roche. Dr. Tardif has received research support from Amarin, AstraZeneca, DalCor, Eli Lilly, Hoffmann-LaRoche, Merck, Pfizer, Sanofi, Cymabay, Novartis, and Servier; has received honoraria from Hoffmann-LaRoche, Pfizer, Servier, AstraZeneca, DalCor, and Valeant; is a shareholder of DalCor; and is an author of a patent that has the findings of genotype-dependent results of dalcetrapib on clinical outcomes as its basis. Dr. Kittelson has received consulting fees from Bayer Healthcare, Cystic Fibrosis Foundation Therapeutics, Novo Nordisk, Genentech, and BioMarin; and has received honoraria for steering committee participation from CPC Clinical Research. Dr. Schwartz, through his institution, has received research grants from Cerenis, The Medicines Company, Resverlogix, Roche, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Dr. Pitts and Ms. Gunzburger contributed equally to this work.

PY - 2016/12/6

Y1 - 2016/12/6

UR - http://www.scopus.com/inward/record.url?scp=84999852030&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.09.932

DO - 10.1016/j.jacc.2016.09.932

M3 - Letter

C2 - 27908356

AN - SCOPUS:84999852030

SN - 0735-1097

VL - 68

SP - 2488

EP - 2490

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 22

ER -

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this